Today: 9 April 2026
Caesars stock jolts on Fertitta takeover chatter — what CZR investors watch next
27 February 2026
1 min read

Caesars stock jolts on Fertitta takeover chatter — what CZR investors watch next

New York, Feb 27, 2026, 08:41 EST — Premarket

  • Caesars shares jumped about 19% on Thursday, following a report that the company might be weighing takeover interest.
  • The report flagged interest from a group linked to Tilman Fertitta, while also noting a possible management buyout.
  • Traders look for more disclosures and signals on financing, with rate swings still in the background.

Shares of Caesars Entertainment (CZR.O) shot up about 19% Friday, after reports that the casino operator is weighing takeover bids—including an offer linked to billionaire Tilman Fertitta, according to Reuters.

Eyes are on Caesars, loaded with U.S. gaming leverage, as the take-private bid hangs on debt markets staying open and not too costly. Caution is setting in among investors. “Headline rallies” have fizzled before, sometimes vanishing the moment a fresh filing lands—or doesn’t.

Caesars is mulling bids from multiple suitors and has even explored a management buyout scenario that would involve company executives teaming up with financial sponsors to take it private, the Financial Times reports. Talks remain active but could still collapse, according to the same report. With debt topping $20 billion, Caesars presents a tough challenge for any potential buyer. Financial Times

The stock closed out Thursday at $24.74, up 19.11%. It swung between $20.85 and $25.08 during the session as volume spiked, with about 16.9 million shares traded. Yahoo Finance

MGM Resorts, Las Vegas Sands, and DraftKings each finished higher, but none matched the surge in Caesars, MarketWatch said. MarketWatch

Caesars Digital just posted its best quarter yet, CEO Tom Reeg said earlier this month. Looking ahead, Reeg told investors that by 2026, the company’s free cash flow is slated for paying down debt and, when the opportunity presents itself, buying back shares—a choice of words that tends to gain significance whenever acquisition chatter picks up around a company carrying this much leverage. Caesars Newsroom

Wall Street showed caution just a day ago. On Wednesday, Morgan Stanley trimmed its Caesars price target to $25 from $27, maintaining an “equal weight” rating, MarketBeat reported. The adjustment underscored how quickly attention shifted away from fundamentals and zeroed in on deal math. MarketBeat

Macro factors are in the mix too. The Labor Department said U.S. producer prices jumped 0.5% in January, with the core PPI—excluding food, energy and trade services—up 0.3%. Numbers like that could shake up rate expectations, and that feeds directly into the cost of funding a leveraged buyout. Bureau of Labor Statistics

Buyout rumors come cheap; the financing, not so much. If would-be acquirers get cold feet over Caesars’ massive debt load, lease commitments, or the daunting amount of cash needed, the stock could quickly reverse course — especially if the company stays silent.

Traders are now waiting for either a statement from Caesars or more concrete reporting. Looking ahead, new U.S. economic data looms next week: the ISM manufacturing PMI lands March 2, followed by February jobs figures on March 6. Both could move yields and appetite for risk ahead of any final deal funding. Investing.com

Stock Market Today

  • AbbVie's Humira Launch on TrumpRx with 86% Discount Sparks Valuation Questions
    April 9, 2026, 9:02 AM EDT. AbbVie (NYSE:ABBV) has introduced Humira on the TrumpRx platform at an 86% discount under a White House pricing deal aiming to reduce patient costs and widen drug access. This marks a significant US pricing strategy shift post exclusivity for Humira, a key immunology therapy driving substantial revenue. The stock trades near $206.69, about 20% below analyst targets and 43.8% under fair value estimates. The deep discount could alter patient volume, payer ties, and pricing benchmarks in government-linked drug programs. AbbVie's revenue exposure of $61.2 billion and a high price-to-earnings ratio of 87.3 place focus on potential impacts to cash flow and dividends amid its debt load. Investors should monitor reactions from payers, competitors, and capital markets to this pricing shift that could redefine AbbVie's US market dynamics.

Latest article

When Will Gas Prices Fall? Iran Ceasefire May Not Bring Quick Relief as Oil Rebounds

When Will Gas Prices Fall? Iran Ceasefire May Not Bring Quick Relief as Oil Rebounds

9 April 2026
Brent crude rebounded 3% Thursday despite a U.S.-Iran ceasefire, with the Strait of Hormuz still nearly shut and only one oil-products tanker passing in 24 hours. U.S. gasoline averaged $4.166 a gallon on April 9, and AAA said prices could drop slowly. North Sea Forties crude hit a record $146.43 a barrel. The U.S. EIA expects Hormuz flows may take months to recover.
CoreWeave Stock Climbs on $21 Billion Meta AI Cloud Deal, but Debt Risks Stay in Focus

CoreWeave Stock Climbs on $21 Billion Meta AI Cloud Deal, but Debt Risks Stay in Focus

9 April 2026
CoreWeave said Meta Platforms committed about $21 billion for AI cloud capacity through December 2032. Shares rose 4.3% to $88.90 in premarket trading after the announcement. The deal follows an $8.5 billion loan facility and a $1.25 billion senior notes offering. CoreWeave reported $5.13 billion in 2025 revenue and ended December with a $66.8 billion backlog.
NVIDIA’s Rubin AI Chip Ramp Hits Fresh Snag as HBM4 Memory Crunch Clouds 2026

NVIDIA’s Rubin AI Chip Ramp Hits Fresh Snag as HBM4 Memory Crunch Clouds 2026

9 April 2026
TrendForce said April 8 that Nvidia’s Rubin AI chip shipments may be delayed by HBM4 memory qualification and cooling demands, shifting over 70% of 2026 high-end GPU volume to the current Blackwell line. Rubin’s projected share dropped to 22%. Samsung began shipping HBM4 to Nvidia in February, but SK Hynix and Micron face qualification delays. Broadcom signed a long-term deal to develop Google’s TPUs through 2031.
UK picks Barclays executive Katharine Braddick to run Bank of England banking watchdog
Previous Story

UK picks Barclays executive Katharine Braddick to run Bank of England banking watchdog

Warby Parker stock slips in premarket after 18% surge on buyback, 2026 outlook
Next Story

Warby Parker stock slips in premarket after 18% surge on buyback, 2026 outlook

Go toTop